Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | OGA | O60502 | 8/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989549 | 1.00 | KDM4E (0.48) | KDM4EGAAHRH3OGASMO | |
| SCHEMBL14349220 | 0.85 | KDM4E (0.52) | KDM4EGAAHRH3OGASMO | |
| SCHEMBL14217156 | 0.84 | ALDH1A1 (0.44) | KDM4EOGAKMT2A | |
| SCHEMBL11989546 | 0.84 | ALDH1A1 (0.44) | KDM4EOGAKMT2A | |
| SCHEMBL11989613 | 0.84 | ALDH1A1 (0.44) | KDM4EOGAKMT2A | |
| SCHEMBL11990174 | 0.84 | UBE2T (0.46) | OGA | |
| SCHEMBL14239253 | 0.83 | KDM4E (0.50) | KDM4EGAAHRH3OGASMO | |
| SCHEMBL11989577 | 0.83 | OGA (0.48) | HRH3OGA | |
| SCHEMBL14217201 | 0.82 | UBE2T (0.45) | KDM4EOGA | |
| SCHEMBL14217158 | 0.82 | UBE2T (0.45) | KDM4EOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530489-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | KDM4E 636/4885GAA 1660/4885HRH3 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.